Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene and Duke to Jointly Develop Biomarkers for Lymphoma, Leukemia

NEW YORK (GenomeWeb News) – Med BioGene this week said it has entered into a research collaboration and option agreement with Duke University to further develop and validate genetic biomarkers for lymphoma and leukemia.
 
Under the terms of the collaboration, which will use MBI’s gene expression-profiling system, Duke will provide MBI a certain number of samples from patients with clinically confirmed lymphoma and leukemia for genetic analysis.
 
Duke and MBI will analyze those results, and Duke will grant MBI an option to acquire exclusive worldwide licensing rights to the intellectual property developed under the collaboration.
 
MBI will reimburse Duke for certain expenditures, and then pay undisclosed royalties to Duke on revenue received from product sales. Duke will be entitled to publish the results of the research, subject to review by MBI.
 
Financial terms of the agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more